Fresenius Kabi and TQ Therapeutics have entered into a strategic-development agreement aimed at improving the scalability and efficiency of cell and gene therapy (CGT) manufacturing. The agreement grants Fresenius Kabi an exclusive licence to develop, manufacture, and distribute products incorporating TQ Therapeutics’ proprietary cell selection technology.
Kupando, a German biopharmaceutical company focused on innate immune stimulation, has appointed Jörn Aldag as Chair of its Board of Directors, signalling a strategic push towards clinical-stage development of its lead TLR 4/7 agonist candidate, KUP101.
iXCells Biotechnologies has appointed Steve Smith as Chief Executive Officer, elevating him from his previous role as Chief Commercial Officer (CCO) as the San Diego-based company expands its induced pluripotent stem cell (iPSC) preclinical services portfolio.
A Stockholm-based biotechnology company, CubaseBio, has emerged from stealth mode with €5.9 million in blended financing to accelerate the commercialisation of a next-generation spatial transcriptomic platform capable of analysing intact three-dimensional tissue structures — a capability that has eluded conventional spatial biology methods.
leon-nanodrugs GmbH has announced a series of significant developments, closing an oversubscribed financing round whilst appointing two senior scientific leaders, as the Munich-based company accelerates its transition into full commercial deployment of its GMP-compatible nanoparticle manufacturing platform.
MIMETAS, the Dutch organ-on-a-chip specialist, is among nine founding members of IAMPS – the Industry Alliance for Microphysiological Systems – launched on 10 February 2026 as the world’s first industry association dedicated to microphysiological systems (MPS) technologies.
Nuclera, the Cambridge-based biotechnology company, and leadXpro, a specialist in structure-based drug discovery headquartered in Villigen, Switzerland, have announced a scientific partnership aimed at improving access to high-quality membrane protein constructs for drug discovery programmes.
HORIBA, Ltd., the Kyoto-based precision instrumentation and measurement group, has announced plans to construct a new global headquarters on the site of its existing head office in Kisshoin, Minami-ku, Kyoto, Japan. Construction commenced in December 2025, with completion scheduled for January 2028 — the year the company marks its 75th anniversary.
London-based Synthace, a software and services company specialising in assay development, has announced a collaboration with Charles River Laboratories International, Inc., a global provider of drug discovery, development, testing and manufacturing solutions. The partnership will give Charles River’s clients access to Synthace’s approach to developing, automating and transferring assays with greater robustness and efficiency.
Capricorn Scientific has announced the opening of a new logistics and infrastructure facility in Ebsdorfergrund, Germany, marking a significant expansion of the company’s European operational capacity in support of regulated biotech, pharma, diagnostics, and cell therapy markets.
March 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.